|[August 25, 2014]
Research and Markets: OpportunityAnalyzer: Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/zzpnxr/opportunityanalyze)
has announced the addition of the "OpportunityAnalyzer:
Graft-Versus-Host Disease - Opportunity Analysis and Forecasts to 2018"
report to their offering.
New Drugs to Boost Graft-Versus-Host Disease Treatment Market by 2018.
The graft-versus-host disease (GVHD) treatment market value will
increase from $297 million in 2013 to $407 million by 2018, at a
Compound Annual Growth Rate (CAGR) of 6.59%, according to research and
consulting firm The authors.
This report provides annualized graft-versus-host disease therapeutics
market revenue, cost of therapies and forecasts from 2013 to 2018 across
six major markets: the US, France, Germany, Italy, Spain and the UK. Key
topics covered include strategic product assessment, market
characterization, unmet needs, research and development strategies,
clinical trial design, pipeline analysis and competitor evaluations.
The report states that this growth, which will occur over six major
makets (6MM: the US, France, Germany, Italy, Spain and the UK), will be
strongest in the five European countries (5EU), where multiple product
launches will accelerate the market value at a CAGR of 9.26% during the
Eirini Vavatsikou, Ph.D., The authors's Analyst covering Immunology,
says: Several products are due to enter the GVHD market by 2018, with
Osiris Therapeutics and Mesoblast's first-to-market Prochymal expected
to generate sales of $12.2 million in 2018.
Dr. Falk Pharma's Budenofalk is forecast to enter the European GVHD
market in 2016, while ATG (News - Alert)-Fresenius (ATG-F) will arrive in the US market
in 2017. These two products are estimated to achieve 2018 sales of
$11,900 and $8 million, respectively.
The authors forecasts that both Jazz Pharmaceuticals' Leukotac and
Adienne Pharma's Begedina will enter the GVHD market in 2018, with
Leukotac being launched only in the 5EU. Due to their anticipated
premium pricing, these drugs are expected to add over $18 million to the
6MM sales by the end of 2018.
While multiple biologic products will fall off their respective patent
cliffs by the end of the forecast period, Vavatsikou states that this
will not impact the GVHD forecast for two important reasons.
The analyst explains: Firstly, biosimilar versions of prominent
off-label GVHD biologics, such as Rituxan and Campath/Lemtrada, are in
very early development and are yet to succeed in clinical trials.
Secondly, hematologists across the 6MM are not expected to use
biosimilar versions of branded biologics in GVHD patients whose health
is already severely compromised.
Furthermore, key opinion leaders interviewed by The authors unanimously
agreed that they would prefer new biosimilars to be tested in a GVHD
clinical trial setting before they use such treatments in the clinic.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
5 Current Treatment Options
6 Unmet Need and Opportunity
7 Research and Development Strategies
8 Pipeline Assessment
9 Pipeline and Off-Label Valuation Analysis
For more information visit http://www.researchandmarkets.com/research/zzpnxr/opportunityanalyze
[ Back To Unified Communications 's Homepage ]